Omics-Based Clinical Trials Market Size, Share, By Phase Type (Phase I, Phase II, Phase III, and Phase IV), By Study Design Type (Interventional Studies, Observational Studies, and Expanded Access Studies), By Indication Type (Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases, and Others), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI555724 | Publish Date: August 2024 | No. of Pages: 184

Omics Based Clinical Trials Market Companies

Recent News:

Mayo's new 'omics' strategy, which will be implemented in May 2024, looks forward. Building on this foundational science, Mayo Clinic's Center for Individualized Medicine has devised a novel "omics" strategy for incorporating precision medicine into normal clinical care. The technique will be useful in Rare Disease Omics, Population Omics, Functional Omics, and Digital Omics. This novel method represents a big leap into a new era of medicine. These four interconnected 'omics' pillars will allow us to broaden our reach, accelerate progress in customized medicine, and transform patient care.
Longitudinal multi-omics monitoring will allow for the early diagnosis of pancreatic cancer in April 2024. A study published in the Journal of Integrative Biology describes how longitudinal multi-omics monitoring (LMOM) helped detect a precancerous pancreatic tumor, leading to a successful surgical intervention. The patient underwent an annual blood-based LMOM, during which 143 endogenous metabolites in serum and 140 proteins in plasma were tested. This case report highlights the promise of blood LMOM for precision/personalized medicine, as well as novel methods to medical innovation for a potentially life-saving early detection of pancreatic cancer.